ATE500837T1 - Molekulare determinanten des multiplen myeloms und deren verwendung - Google Patents

Molekulare determinanten des multiplen myeloms und deren verwendung

Info

Publication number
ATE500837T1
ATE500837T1 AT07118621T AT07118621T ATE500837T1 AT E500837 T1 ATE500837 T1 AT E500837T1 AT 07118621 T AT07118621 T AT 07118621T AT 07118621 T AT07118621 T AT 07118621T AT E500837 T1 ATE500837 T1 AT E500837T1
Authority
AT
Austria
Prior art keywords
multiple myeloma
lytic
lesions
bone
bone disease
Prior art date
Application number
AT07118621T
Other languages
English (en)
Inventor
John Shaughnessy
Original Assignee
Univ Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas filed Critical Univ Arkansas
Application granted granted Critical
Publication of ATE500837T1 publication Critical patent/ATE500837T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
AT07118621T 2002-12-05 2003-12-04 Molekulare determinanten des multiplen myeloms und deren verwendung ATE500837T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43104002P 2002-12-05 2002-12-05

Publications (1)

Publication Number Publication Date
ATE500837T1 true ATE500837T1 (de) 2011-03-15

Family

ID=32507666

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07118621T ATE500837T1 (de) 2002-12-05 2003-12-04 Molekulare determinanten des multiplen myeloms und deren verwendung

Country Status (11)

Country Link
US (1) US7459437B2 (de)
EP (2) EP1913952B1 (de)
JP (2) JP4874549B2 (de)
AT (1) ATE500837T1 (de)
AU (1) AU2003302926A1 (de)
CA (1) CA2507496C (de)
DE (1) DE60336356D1 (de)
ES (1) ES2362681T3 (de)
MX (1) MXPA05006033A (de)
PT (1) PT1913952E (de)
WO (1) WO2004053063A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811750B2 (en) * 2002-12-05 2010-10-12 Board Of Trustees Of The University Of Arkansas Molecular determinants of myeloma bone disease and use thereof
WO2005070448A2 (en) * 2004-01-21 2005-08-04 Five Prime Therapeutics, Inc. Methods of use for secreted frizzled-related protein 3 (sfrp-3) in the prevention and treatment of disease
WO2006015373A2 (en) * 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
WO2006061430A2 (en) * 2004-12-10 2006-06-15 Proskelia Bone metastasis markers as a target regulating bone metastasis and bone development
JP2006217844A (ja) * 2005-02-09 2006-08-24 Univ Of Tokyo Ｄｋｋ１の遺伝子、蛋白質及び抗体を用いた癌の診断・モニター方法及び治療方法
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2007104181A1 (en) * 2006-03-13 2007-09-20 Shanghai Cancer Institute Uses of dkk-1 protein in diagnosis of cancers
ES2526928T3 (es) 2008-04-30 2015-01-16 The Governing Council Of The University Of Toronto Uso de SFRP-3 en la evaluación de la insuficiencia cardíaca
NZ596274A (en) 2009-05-12 2013-11-29 Pfizer Blocking anti-dkk-1 antibodies and their uses
JP5894581B2 (ja) * 2010-05-21 2016-03-30 ウニヴェルズィテート・フューア・ボーデンクルトゥーア・ウィーン 骨障害及び／又は心血管障害の治療又は診断に使用する組成物
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
WO2013010074A1 (en) 2011-07-13 2013-01-17 Primeradx, Inc. Multimodal methods for simultaneous detection and quantification of multiple nucleic acids in a sample
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
AU2014360426B2 (en) 2013-12-06 2020-05-07 Dana-Farber Cancer Institute, Inc. Methods to distinguish Waldenstrom's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
EP3079683A4 (de) 2013-12-13 2017-12-20 Dana-Farber Cancer Institute, Inc. Verfahren zur behandlung eines lymphoplasmazytischen lymphoms
JP2019518006A (ja) 2016-04-29 2019-06-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ
KR20220098732A (ko) 2019-10-08 2022-07-12 다나-파버 캔서 인스티튜트 인크. 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052047A2 (en) * 1999-03-05 2000-09-08 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
MXPA02002624A (es) * 1999-09-13 2002-07-30 Wyeth Corp Composiciones farmaceuticas y metodos de uso de proteinas secretadas relacionadas con la familia "frizzled".
JP2005512508A (ja) * 2001-05-17 2005-05-12 ゲノム　セラピューティックス　コーポレーション Ｄｋｋ媒介性相互作用を変調する試薬および方法
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions

Also Published As

Publication number Publication date
EP1567663A2 (de) 2005-08-31
JP2012046535A (ja) 2012-03-08
CA2507496C (en) 2014-11-04
EP1913952A1 (de) 2008-04-23
EP1913952B1 (de) 2011-03-09
ES2362681T3 (es) 2011-07-11
WO2004053063A3 (en) 2004-11-25
AU2003302926A1 (en) 2004-06-30
US7459437B2 (en) 2008-12-02
PT1913952E (pt) 2011-04-14
AU2003302926A8 (en) 2004-06-30
MXPA05006033A (es) 2006-03-08
JP4874549B2 (ja) 2012-02-15
WO2004053063A2 (en) 2004-06-24
US20040137489A1 (en) 2004-07-15
CA2507496A1 (en) 2004-06-24
DE60336356D1 (de) 2011-04-21
JP2006512911A (ja) 2006-04-20
JP5432966B2 (ja) 2014-03-05
EP1567663A4 (de) 2006-04-19

Similar Documents

Publication Publication Date Title
ATE500837T1 (de) Molekulare determinanten des multiplen myeloms und deren verwendung
Cicuttini et al. Genetics of osteoarthritis.
Hočevar et al. The possible influence of genetic aetiological factors on molar–incisor hypomineralisation
Tiziani et al. The gene for cherubism maps to chromosome 4p16
Montes et al. Analysis of the association of IL1B (C+ 3954T) and IL1RN (intron 2) polymorphisms with dental implant loss in a Brazilian population
Antunes et al. Analysis of the association between polymorphisms in MMP2, MMP3, MMP9, MMP20, TIMP1, and TIMP2 genes with white spot lesions and early childhood caries
DE50304683D1 (de) Bipolares medizinisches instrument sowie elektrochirurgisches system mit einem solchen instrument
Singh et al. Identification of matrix metalloproteinases and their tissue inhibitors type 1 and 2 in human masseter muscle
Noto et al. Dyskeratosis congenita associated with leukoplakia of the tongue
White et al. Kindler surprise: mutations in a novel actin-associated protein cause Kindler syndrome
EP1551392A4 (de) NEUE LAPACHO-VERBINDUNGEN UND ANWENDUNGSVERFAHREN DAFüR
Ebersole et al. Comparative analysis of gene expression patterns for oral epithelium-related functions with aging
Raza et al. A novel homozygous nonsense mutation in the PVRL4 gene and expansion of clinical spectrum of EDSS1
Kjaer et al. HOXD13 polyalanine tract expansion in classical synpolydactyly type Vordingborg
Hsiao et al. Matrix metalloproteinase-2,-9, and tissue inhibitor of MMP-2 gene polymorphisms in Taiwanese periodontitis patients
Van Pham Tissue engineering and regenerative medicine
Colletti et al. Epidermal nevus and ameloblastoma: a rare association
Luo et al. Association of COL1A1 polymorphism with subchondral bone degeneration of the temporomandibular joint
DE60320055D1 (de) Legierung auf Kupferbasis und Verfahren zur Herstellung von hochfestem Schmiedestück mit hoher Wärmeleitfähigkeit, das diese Legierung verwendet
Avcin et al. Early-onset osteoarthritis due to otospondylomegaepiphyseal dysplasia in a family with a novel splicing mutation of the COL11A2 gene.
Broker et al. Clinical aspects and polymorphisms in the LTA, TNFA, LTB genes and association with dental implant loss
Allende et al. A genetic study of cathepsin C gene in two families with Papillon–Lefèvre syndrome
Amaral et al. WWOX expression in giant cell lesions of the jaws
Ren et al. Prevalence of eruption of third molar tooth among South Indians and Malaysians
Mohanan et al. Assessment of Salivary Flow Rate and Antioxidant Levels in Ectodermal Dysplasia Patients: An: In vivo: Study

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1913952

Country of ref document: EP